Lori-Ann Linkins, MD, FRCP(C); Peter T. Choi, MD, MSc, FRCP(C); James D. Douketis, MD, FRCP(C)
Acknowledgments: The authors thank Drs. Clive Kearon, Mark Crowther, Lehana Thabane, and Jack Hirsh for their helpful reviews of the manuscript.
Grant Support: Dr. Linkins is the recipient of a Fellowship Award from the Heart & Stroke Scientific Research Corporation of Canada/AstraZeneca Canada, Inc. Dr. Douketis is a recipient of a Research Scholarship from the Heart and Stroke Foundation of Canada.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: James D. Douketis, MD, FRCP(C), St. Joseph's Healthcare, Room F-541, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada; e-mail, email@example.com.
Current Author Addresses: Dr. Linkins: Henderson Research Centre, Room 220, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada.
Dr. Choi: Department of Anesthesia, University of British Columbia, 2329 West Mall, Vancouver V6T 1Z4, British Columbia.
Dr. Douketis: St. Joseph's Healthcare, Room F-541, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada.
Author Contributions: Conception and design: L.A. Linkins, J.D. Douketis.
Analysis and interpretation of the data: L.A. Linkins, P.T. Choi, J.D. Douketis.
Drafting of the article: L.A. Linkins, J.D. Douketis.
Critical revision of the article for important intellectual content: L.A. Linkins, P.T. Choi, J.D. Douketis.
Final approval of the article: L.A. Linkins, P.T. Choi, J.D. Douketis.
Statistical expertise: P.T. Choi.
Administrative, technical, or logistic support: J.D. Douketis.
Collection and assembly of data: L.A. Linkins.
Clinicians should consider the clinical impact of anticoagulant-related bleeding when deciding on the duration of anticoagulant therapy in patients with venous thromboembolism.
To provide reliable estimates of the clinical impact of anticoagulant-related bleeding, defined as the case-fatality rate of major bleeding and the risk for intracranial bleeding.
MEDLINE (January 1989 to May 2003), Cochrane Controlled Trial Registry, thromboembolism experts, and reference lists; English-language literature only.
Randomized, controlled trials and prospective cohort studies that investigated patients with venous thromboembolism who received oral anticoagulant therapy (target international normalized ratio, 2.0 to 3.0) for at least 3 months and that reported major bleeding and death as primary study outcomes.
Two reviewers independently extracted data on the number of anticoagulant-related major and intracranial bleeding episodes and on whether these events were fatal or nonfatal.
The authors analyzed 33 studies involving 4374 patient-years of oral anticoagulant therapy. For all patients, the case-fatality rate of major bleeding was 13.4% (95% CI, 9.4% to 17.4%) and the rate of intracranial bleeding was 1.15 per 100 patient-years (CI, 1.14 to 1.16 per 100 patient-years). For patients who received anticoagulant therapy for more than 3 months, the case-fatality rate of major bleeding was 9.1% (CI, 2.5% to 21.7%), and the rate of intracranial bleeding was 0.65 per 100 patient-years (CI, 0.63 to 0.68 per 100 patient-years) after the initial 3 months of anticoagulation.
The clinical impact of anticoagulant-related major bleeding in patients with venous thromboembolism is considerable, and clinicians should take this into account when deciding whether to continue long-term oral anticoagulant therapy in an individual patient.
Linkins L, Choi PT, Douketis JD. Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis. Ann Intern Med. 2003;139:893–900. doi: https://doi.org/10.7326/0003-4819-139-11-200312020-00007
Download citation file:
Published: Ann Intern Med. 2003;139(11):893-900.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use